Evotec Teams with Novo Nordisk for LAB eN² Drug Discovery Launch

• Evotec SE and Novo Nordisk have selected three projects from Boston University, Harvard University (in collaboration with Mass General Brigham), and Joslin Diabetes Center to develop within the LAB eN² drug discovery accelerator, focusing on cardiometabolic diseases.
• LAB eN² is expanding to include five additional institutions: Boston Children’s Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and Icahn School of Medicine at Mount Sinai.
• The selected projects will address chronic kidney disease, metabolic syndrome, and type 1 diabetes, with initial funding provided through a Discovery Award.
• Evotec aims to accelerate the translation of academic discoveries into investigational new drug candidates for cardiometabolic diseases and rare disorders through LAB eN².
• The initiative was launched in September 2023 with four academic institutions and has now expanded to include additional researchers and projects.
• LAB eN² provides funding, scientific expertise, and technology to advance drug discovery programs, with the potential for further investment from Novo Nordisk after reaching key pre-clinical milestones.

The next important date, Publication Annual Financial Report, at Evotec is on 17.04.2025.

The price of Evotec at the time of the news was 9,2125EUR and was up +4,54 % compared with the previous day.
15 minutes after the article was published, the price was 8,9875EUR this corresponds to a minus of -2,44 % since publication.
At this time, the index SDAX was at 14.120,56PKT (+0,41 %).

Evotec

+1,75 %

-5,23 %

-28,02 %

-27,10 %

-58,98 %

-79,07 %

-70,95 %

+60,03 %

+633,73 %

ISIN:DE0005664809WKN:566480

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max